Redefining Radial Closure.

Clinically. Comfortably. Clearly.

Get in touch

SĀPH (Suction Activated Patent Hemostasis) represents a non-compressive, suction-based approach to radial closure that works with blood flow, not against it.

Leveraging a proprietary suction mechanism, it achieves hemostasis by gently drawing the artery to a soft external seal—without circumferential or downward compression. SĀPH is designed to help minimize the risk of Radial Artery Occlusion (RAO), reduce post-procedure staff burden, and enhance patient comfort.

Developed by a leading interventional cardiologist, SĀPH emphasizes efficiency and simplicity—supporting smoother procedures, preserving future access, and redefining the standard for pain-free closure.

How it works

Why SĀPH matters

When was the last time you had a real conversation about improving radial closure–RAO, comfort, staff time?

There are limitations to the conventional radial compression mechanisms of action.

Pain

Conventional compression leaves patients rating pain 6 out of 10. [1]

Time

Time intensive for Cath Lab staff (up to 50 minutes) [2]

Radial access is now the gold standard.

  • 60% of PCIs in the U.S. use radial (up from 14% in 2011) [4]

  • Chosen for: Safety, speed, and patient comfort

But closure hasn’t kept up.

  • No real innovation in closure devices since radial’s rise

  • Most still rely on circumferential or occlusive compression.

What’s different about SĀPH

Complications

Radial Artery Occlusion (RAO) still occurs in 5–10% of cases. [3]

SĀPH is designed to streamline radial closure and reduce staff burden.

Precise Alignment

SĀPH features a notch-guided design to support accurate positioning over the access site — helping clinicians align closure with confidence.

Targeted Closure Support

SĀPH is a completely topical system — nothing subdermal. Its integrated keel element is designed to support apposition at the arteriotomy site, enabling closure without introducing material beneath the skin.

Predictable Deployment

A simplified design with intuitive visual markers allows consistent setup and reproducibility across a range of experience levels.

Efficient Hemostasis

SĀPH utilizes a proprietary suction-based mechanism to gently approximate the arteriotomy up against the subdermal tissue —promoting effective seal formation without circumferential compression.

Streamlined Workflow

SĀPH reduces complexity at the bedside: minimizes manual pressure and adjustments; post-procedure monitoring per site protocol.

Evidence at a Glance

  • Device directly addresses RAO by maintaining flow during closure.

    Rashid et al., 2016 (JAHA) – Meta-analysis of RAO

    Explore the evidence

  • Confirms the advantage of flow-preserving, non-compressive closure—SĀPH achieves this through suction-based hemostasis.

    Minor et al., 2021 (J Invasive Cardiol) – Randomized Trial of VasoStat vs TR Band

    Explore the evidence

  • Eliminates uncertainty around banding protocols by achieving immediate, patent hemostasis without prolonged compression.

    Maqsood et al., 2023 (Circ Cardiovasc Interv) – Meta-analysis of Hemostasis Band

    Explore the evidence

  • By preserving flow without compression, SĀPH directly addresses the key causes of RAO.

    Avdikos et al., 2017 (Cardiovasc Diagn Ther) – Review of Radial Artery Occlusion

    Explore the evidence

  • Underscores the need for safer, flow-preserving closure without added radiation—what SĀPH delivers.

    Dobies et al., 2016 (Open Heart) – Registry Analysis of Radial vs Femoral PCI

    Explore the evidence

“The current hemo static therapies take time and create repetitive tasks from the nursing staff to remove the air. I see that the air removal protocols cannot realistically be followed.

Also, radial artery occlusion is a growing issue. Patients are coming in, sometimes at a young age and your typical CAD patient is going to require multiple caths throughout their lifetime, we hate to lose an access site.”

Bailey Estes

AGNP-C, MSN; Cardiac Cath Lab Scrub Nurse and Researcher; Co-Chair of the ACC Cardiovascular Team Communications Work Group; Cath Lab Digest Editorial Board Greater Abilene Area

About us

Transradial Technologies, Inc. is a medical device company focused on developing a novel, minimally invasive transradial vascular closure device.

Transradial Technologies, Inc. has worldwide and exclusive rights to the technology via an agreement with Transradial Holdings, Inc.

About us

Contact us